Cumberland Pharmaceuticals Inc. (CPIX) Stock Score, Valuation & Financial Research
Cumberland Pharmaceuticals Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for CPIX
Cumberland Pharmaceuticals Inc. currently has a Wall Street Score of 24/100. The stored market price is $6.98. Its financial score is 32/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Cumberland Pharmaceuticals Inc. does
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including t
CPIX financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $6.98
- Market capitalization:
- $104.6M
- Revenue:
- $31.3M
- Net income:
- $-10.6M
- Free cash flow:
- $4.8M
- Cash:
- $3.9M
- Total debt:
- $4.7M
- EPS:
- -0.71
- Financial score:
- 32/100
- Valuation score:
- 0/100
- Revenue score:
- 8/100
What stands out
- Reported year-over-year revenue growth is -0.3%.
- Free cash flow is $4.8M, showing positive cash generation.
- The balance sheet shows $3.9M of cash versus $4.7M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 32/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CPIX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.